RxDoctor Payments Data

Julia Adrogue, MD

Interventional Cardiology · Sugar Land, TXNPI 1659510196

Payments from drug & device makers

$8,805in general payments, 2019–2025

Across 398 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$823
  • Abbott$718
  • Artivion, Inc.$712
  • Amgen$694
  • E.r. Squibb & Sons, L.L.C.$635
  • Novartis$547
  • plus $5K from 37 others

What the payments were for

  • Travel & lodging$7128%
  • Food & beverage$8,07592%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,805 in reported general payments places this provider in the 40th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$353,395
Medicare patients
1,427
Services billed
5,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban289$308,559
XareltoRivaroxaban133$177,865
Repatha SureclickEvolocumab85$97,772
EntrestoSacubitril/Valsartan46$68,177
BrilintaTicagrelor11$10,329
Metoprolol Succinate656$9,763
Losartan Potassium575$6,267
Ezetimibe183$5,318
Flecainide Acetate156$4,501
Nifedipine ErNifedipine131$4,479
Rosuvastatin Calcium214$3,076
Atorvastatin Calcium246$3,052
Amlodipine Besylate507$2,919
Potassium Chloride195$2,741
Pravastatin Sodium191$2,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$308,559289 claims
Johnson & JohnsonXarelto$823$177,865133 claims
NovartisEntresto$547$68,17746 claims
AstraZenecaBrilinta$500$10,32911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →